Transdermal rotigotine: a new non-ergot dopamine agonist for the treatment of Parkinson’s disease

Bibliography

• CLOUGH CG, CHAUDHURI KR, SETHI KD: Parkinson’s disease. Health Press, Oxford (2003):7-19.
   Google Scholar
• HOEHN MM, YAHR MD: Parkinsonism: onset, progression and mortality. Neurology (1967) 17:427-442.
   PubMed Web of Science ®Google Scholar
• CHAUDHURI K R, HEALY D, SCHAPIRA AHV: The non-motor symptoms of Parkinson’s disease. Diagnosis and management. Lancet neurology (2006) 5:235-245.
   PubMed Web of Science ®Google Scholar
• OLANOW CW, WATTS RL, KOLLER WC: An algorithm (decision tree) for the management of Parkinson’s disease (2001): Treatment guidelines. Neurology (2001) 56(5):S1-S88.
   PubMed Web of Science ®Google Scholar
• MARSDEN CD, PARKES JD: Success and problems of long-term levodopa therapy in Parkinson’s disease. Lancet (1977) 1:345-349.
   PubMed Web of Science ®Google Scholar
• RAJPUT AH, FENTON ME, BIRDI S et al.: Clinical-pathological study of levodopa complications. Mov. Disord. (2002) 17:289-296.
   PubMed Web of Science ®Google Scholar
• RASCOL O, GOETZ C, KOLLER W, SIMPATICO C: Treatment interventions for Parkinson's disease: an evidence based assessment. Lancet (2002) 359:1589-1598.
   PubMed Web of Science ®Google Scholar
• OLANOW W, SCHAPIRA AH, RASCOL O: Continuous dopamine- receptor stimulation in early Parkinson’s Disease. Trends Neurosci. (2000) 23: S117-126.
   PubMed Web of Science ®Google Scholar
• STOCCHI F, VACCA L, RUGGIERI S et al.: Intermittent vs. continuous levodopa administration in patients with advanced Parkinson’s disease; a clinical and pharmacokinetic study. Arch. Neurol. (2005) 62:905-910.
   PubMed Web of Science ®Google Scholar
• DHAWAN V, HEALY D, PAL S, CHAUDHURI KR: The sleep related problems of Parkinson’s disease. Age Ageing (2006) 35:220-228.
   Web of Science ®Google Scholar
• NYHOLM D, ASKMARK H, GOMES-TROLIN C et al.: Optimising Levodopa pharmacokinetics: Intestinal infusion versus oral sustained –release tablets. Clin. Neuropharmacol. (2003) 26(3):156-163.
   PubMed Web of Science ®Google Scholar
• MANSON AJ, TURNER K, LEES AJ: Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson’s disease: long-term follow up study of 64 patients. Mov. Disord. (2002) 17(6):1235-1241.
   PubMed Web of Science ®Google Scholar
• KATZENSCHLAGER R, Hughes A, Evans A et al.: Continuous subcutaneous apomorphine therapy improves dyskinesias in PD: a prospective study using single –dose challenges. Mov. Disord. (2005) 20:151-157.
   PubMed Web of Science ®Google Scholar
• OBESO JA, LUQUIN MR, MARTINEZ-LAGE JM: Lisuride infusion pump: a device for the treatment of motor fluctuations in Parkinson's disease. Lancet (1986) 1:467-470.
   PubMed Web of Science ®Google Scholar
• KOLLER WC, HUTTON JT, TOLOSA E et al.: Immediate –release and controlled release carbidopa/levodopa in PD: a 5-year randomized multicenter study. Carbidopa/Levodopa study Group. Neurology (1999) 53:1012-1019.
   PubMed Web of Science ®Google Scholar
• RASCOL O:Transdermal delivery of dopaminergic agents. Neurology (2005) 65(1): S1- S2.
   PubMed Web of Science ®Google Scholar
• GROSSET KA, BONE I, GROSSET DG: Suboptimal medication adherence in Parkinson’s disease. Mov. Disord. (2005) 20:1502-1507.
   PubMed Web of Science ®Google Scholar
• GROSSET D: The rotigotine transdermal patch may provide continuous dopaminergic stimulation in Early- stage Parkinson’s disease. Adv. Clin. Neurol. Rehab. (2006) 6(2):32-34.
   Google Scholar
• JENNER P: A novel dopamine agonist for the transdermal treatment of Parkinson’s disease. Neurology (2005) 65(1) S3 –S5.
   PubMedGoogle Scholar
• HEINDL M, SCHELLER D, LEBSANFT K et al.: Continuous versus discontinuous administration of rotigotine in a rat model of dyskinesias. Parkinsonis and Related Disorders (2005) 11(2): PS002-PS006.
   Google Scholar
• POEWE W, LUESSI F: Clinical studies with transdermal rotigotine in early Parkinson’s Disease. Neurology (2005) 659(1): S11-S14.
   Google Scholar
• ROTIGOTINE (NEUPRO) Summary of product characteristics. Schwarz Pharma.
   Google Scholar
• PAUL ML, GRAYBIEL AM, DAVID JC et al.: D1-like and D2-like dopamine receptors synergistically activate rotation and c-fos expression in the dopamine-depleted striatum in a rat model of Parkinson's disease. Journal of Neuroscience (1992) 12:3729-3742.
   PubMed Web of Science ®Google Scholar
• HORVATH J, FROSS RD, KLEINER- FISMAN G et al.: Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists. Mov. Disord. (2004) 19:656-662.
   PubMed Web of Science ®Google Scholar
• HOROWSKI R, JAHNICHEN S, PERTZ HH: Fibrotic valvular heart disease is not related to chemical class but to biological function; 5-HT2B receptor activation plays crucial role. Mov. Disord. (2004) 19:1523-1524.
   PubMed Web of Science ®Google Scholar
• BARA-JIMENEz W, BIBBIANI F, MORRIS MJ et al.: Effects of serotonin 5-HT1A receptor agonist in advanced Parkinson’s disease. Mov. Disord. (2005) 20:932-936.
   PubMed Web of Science ®Google Scholar
• TOMIYAMA M, KIMURA T, MAEDA T et al.: serotonin 5-HT1A receptor agonist prevents behavioral sensitization to L-DOPA in a rodent model of PD. Neurosci. Res. (2005) 52:185-194.
   PubMed Web of Science ®Google Scholar
• SRINIVASAN J, SCHMIDT WJ: Treatment with alpha2 –adrenoceptor antagonists, 2 methoxy idazaoxan, protects 6- hydroxydopamine induced Parkinsonian symptoms in rats: neurochemical and behavioral evidence. Behav. Brain Res. (2004) 154:353-363.
   PubMed Web of Science ®Google Scholar
• MUCKE HA: Rotigotine. Schwarz Pharma. Drugs (2003) 6:894-899.
   Google Scholar
• The Parkinson StudyGroup: A controlled trial of rotigotine monotherapy in early Parkinson's disease. Arch. Neurol. (2003) 60:1721-1728.
   PubMed Web of Science ®Google Scholar
• WATTS RL, WENDT RL, NAUSIEDA B: Efficacy, safety and tolerability of the rotigotine patch in patients with early stage idiopathic Parkinson’s Disease: multicentre, multinational, randomized, double blinded placebo controlled trial. Mov. Disord. (2004) 19(9): S258.
   Google Scholar
• LEWITT PA, CHANG FL, Rotigotine transdermal system in treatment of patients with advanced stage Parkinson’s disease. Eur. J. Neurol. (2005) 12(Suppl. 2):15 (SC 115) Abstract.
   Google Scholar
• POEWE W, GILADI N, MAGUIRE D, BOROOJERDI B: Rotigotine transdermal patch in patients with Parkinson’s Disease and motor fluctuations. 24h symptom control in a placebo- and pramipexole-controlled, randomized, doubleblind, double dummy trial Eur. J. Neurol. (2006) 13(Suppl. 2): 74(P1126) Abstract.
   Google Scholar
• JANKOVIC JJ: Therapeutic strategies in Parkinson’s disease. In: Parkinson’s disease and movement disorders. Jankovic JJ, Tolosa E (Eds) Lippincott Williams & Wilkins, Philadelphia (2002):116-151.
   Google Scholar
• LEWITT PA, POEWE W, RASCOL O, GILADI N, PATTON J. Overnight switch from ropinirole, pramipexole and cabergoline to rotigotine transdermal patch. Eur. J. Neurol. (2006) 13(Suppl. 2):321 SAT8-3.
   Google Scholar
• STIASNY-KOLSTER K, KOHNEN R, SCHOLLMAYER E et al.: The Rotigotine Sp 666 Study Group. Patch application of the dopamine agonist rotigotine to patients with moderate to advanced stages of restless legs syndrome: a double-blind, placebo-controlled pilot study. Mov. Disord. (2004) 19:1432-1438.
   PubMed Web of Science ®Google Scholar